During the past decade, University Hospital of Salamanca conducted 16 clinical trials. In the 10-year time frame, 16 clinical trials started and 4 clinical trials were completed, i.e. on average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 3 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University Hospital of Salamanca" #1 sponsor was "Red de Terapia Celular" with 2 trials, followed by "AORTICA Group" with 1 trials sponsored, "Affimed GmbH" with 1 trials sponsored, "BioLineRx, Ltd." with 1 trials sponsored and "CTI BioPharma" with 1 trials sponsored. Other sponsors include 14 different institutions and companies that sponsored additional 24 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University Hospital of Salamanca" #1 collaborator was "Haematology Service,University Hospital of Salamanca, MªConsuelo del Cañizo Fernández-Roldán" with 3 trials as a collaborator, "Merck Sharp & Dohme LLC" with 2 trials as a collaborator, "Spanish National Health System" with 2 trials as a collaborator, "Castilla y León Hematology and hemotherapy Foundation" with 1 trials as a collaborator and "European Research Council" with 1 trials as a collaborator. Other collaborators include 7 different institutions and companies that were collaborators in the rest 17 trials.

According to Clinical.Site data, the most researched conditions in "University Hospital of Salamanca" are "Multiple Myeloma" (5 trials), "Myelofibrosis" (2 trials), "Primary Myelofibrosis" (2 trials), "Acute Myeloid Leukemia" (1 trials) and "Aspergillus" (1 trials). Many other conditions were trialed in "University Hospital of Salamanca" in a lesser frequency.

Most popular intervention types in "University Hospital of Salamanca" are "Drug" (15 trials), "Biological" (5 trials), "Procedure" (4 trials), "Device" (3 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Daratumumab" (2 trials), "Dexamethasone" (2 trials), "Pembrolizumab" (2 trials), "TL-895" (2 trials) and "17mm aortic valve (On-X )" (1 trials). Other intervention names were less common.

The vast majority of trials in "University Hospital of Salamanca" are 25 trials for "All" genders.

Currently, there are NaN active trials in "University Hospital of Salamanca". undefined are not yet recruiting, 6 are recruiting, 5 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 10 completed trials in University Hospital of Salamanca, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in University Hospital of Salamanca, 5 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".